Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria...

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...

SAFE PRINT 360 - DEFENDER AGAINST BACTERIA Cincinnati, Ohio - Northern Kentucky, March 10, 2021 (GLOBE NEWSWIRE) -- Introducing Safe Print 360, Flottman Company’s new antimicrobial substrate coating, formulated to inhibit 99% of bacterial...